Targeted alpha therapy: One compound holds promise for unified cancer care
Oak Ridge National Laboratory is fast‑tracking next‑generation targeted alpha therapies—using isotopes like actinium‑225, lead‑212 and actinium‑227—through new chelator chemistry and a unified theranostic program that could diagnose and treat cancers in one go.
